Welcome to our dedicated page for Aim Immunotech news (Ticker: AIM), a resource for investors and traders seeking the latest updates and insights on Aim Immunotech stock.
AIM ImmunoTech Inc. (NYSE American: AIM) is a pioneering immuno-pharma company based in Ocala, Florida, focused on the research and development of innovative therapeutics aimed at treating a variety of cancers, immune disorders, and viral diseases including COVID-19. The company's flagship product is Ampligen® (rintatolimod), a first-in-class investigational drug that acts as a highly selective TLR3 agonist immuno-modulator with broad-spectrum activity. Ampligen is currently undergoing extensive clinical trials targeting globally important cancers and viral diseases.
AIM ImmunoTech's product portfolio also includes Alferon N Injection, an injectable formulation of natural alpha interferon used to treat a specific category of genital warts, a sexually transmitted disease. Ampligen has shown promising results in the treatment of chronic fatigue syndrome and is being developed for other indications like hepatitis B, HIV, and several cancer types, including renal cell carcinoma, malignant melanoma, non-small cell lung cancer, ovarian cancer, breast cancer, colorectal cancer, urothelial cancer, prostate cancer, and pancreatic cancer.
In recent developments, AIM ImmunoTech announced positive top-line interim data indicating that the combination of Ampligen with Keytruda (pembrolizumab) could be significantly more effective than pembrolizumab alone in treating recurrent ovarian cancer. The company is also working on various clinical trials, including studies for treating post-COVID conditions and long COVID, led by renowned medical experts like Dr. Charles Lapp.
AIM ImmunoTech has formed strategic research agreements with prominent institutions such as the Japanese National Institute of Infectious Diseases and Shionogi & Co., Ltd., exploring the potential of Ampligen as an adjuvant therapy for COVID-19. The company continues to focus on operational execution and has successfully completed cGMP manufacturing of over 9,000 clinical vials of Ampligen, which is crucial for its ongoing and upcoming clinical trials.
The company's leadership team, headed by CEO Thomas K. Equels, is committed to advancing its pipeline and achieving clinical and commercial success. AIM ImmunoTech engages with its stakeholders through regular updates and CEO Corner segments, providing insights into its clinical programs and financial performance, ensuring transparency and fostering investor confidence.
For more detailed information, visit the official website and connect with AIM ImmunoTech on social media platforms such as X, LinkedIn, and Facebook.
AIM ImmunoTech (NYSE American: AIM) announced the print publication of data analysis from a long-term Early Access Program studying Ampligen® (rintatolimod) for treating advanced pancreatic ductal adenocarcinoma (PDAC) in Clinical Cancer Research. The study, conducted at Erasmus University Medical Center, found that Ampligen enhances peripheral immune activity in pancreatic cancer patients, particularly involving type 1 conventional dendritic cells and T cells.
Key findings include:
- Increased peripheral abundance of BTLA+XCR1+ cDC1s and CD4+SELL+ T cells correlated with improved clinical outcomes
- Decreased expression of immune checkpoints PD-L1 and PD-L2 post-Ampligen
- Potential for Ampligen to improve progression-free survival and overall survival
AIM ImmunoTech Inc. (NYSE American: AIM) reported its Q2 2024 financial results and provided a corporate update. Key highlights include:
Financial Results:
- Cash, cash equivalents, and marketable securities: $10.1 million as of June 30, 2024
- R&D expenses: $1.1 million for Q2 2024, down from $3.0 million in Q2 2023
- G&A expenses: $2.6 million for Q2 2024, unchanged from Q2 2023
- Net loss: $1.8 million ($0.03 per share) for Q2 2024, compared to $4.9 million ($0.10 per share) in Q2 2023
Corporate Updates:
- New positive data on Ampligen's anti-tumor potential in melanoma treatment
- Publication of results in the peer-reviewed journal Vaccines
- Continued progress in Ampligen clinical development programs
AIM ImmunoTech Inc. (NYSE American: AIM) has announced a conference call and webcast to discuss its Q2 2024 operational and financial results on Friday, August 16, 2024, at 8:30 AM ET. The call will be hosted by CEO Thomas K. Equels and Scientific Officer Christopher McAleer, PhD. Investors can access the call by dialing (877) 407-9219 (domestic) or (201) 689-8852 (international), referencing the AIM ImmunoTech Conference Call. The webcast will be available on the company's website, aimimmuno.com, in the Investors section's Events page and will be archived for 90 days after the event.
AIM ImmunoTech Inc. (NYSE American: AIM) has released a new CEO Corner segment on its website. In this segment, CEO Thomas Equels discusses the positive data from the Phase 1 clinical trial that investigated an Ampligen-containing chemokine modulation therapy used in combination with the chemotherapy drug paclitaxel. The trial focused on the treatment of early stage, triple-negative breast cancer. This update provides investors with insights into the company's progress in developing potential cancer treatments and its ongoing clinical research efforts.
AIM ImmunoTech Inc. (NYSE American: AIM) has announced new pre-clinical data on its drug Ampligen as part of a combination therapy for melanoma treatment. The study, published in the journal Vaccines, shows that combining dendritic cell-based vaccines with anti-PD-L1 checkpoint inhibitors and Ampligen-containing chemokine modulation helped slow tumor cell growth and improved survival in a mouse model.
Dr. David Strayer, AIM's Medical Officer, stated that this data further demonstrates Ampligen's therapeutic potential when used with dendritic-cell vaccines, anti-PD-L1 checkpoint inhibitors, or in combination with both. The company believes this supports their ongoing development of Ampligen as an anti-tumor therapy.
AIM ImmunoTech announced the release of a new CEO Corner segment on their website. CEO Thomas Equels provided updates on the Phase 1b/2 DURIPANC study for a combination therapy of Ampligen and AstraZeneca's Imfinzi targeting late-stage pancreatic cancer. Additionally, the company reported a stockholders' equity of $6.9 million as a result of recent financings. The full CEO Corner segment can be accessed on the company's website.
AIM ImmunoTech will participate in the Virtual Investor Pitch Conference on June 17, 2024, at 1:00 PM ET. CEO Thomas K. Equels will deliver an elevator pitch outlining the company's upcoming milestones. Investors can submit questions live during the event, with responses provided within the time constraints. The live video webcast will be available on AIM ImmunoTech's website, with a replay accessible for 90 days.
AIM ImmunoTech (NYSE American: AIM) announced that CEO Thomas K. Equels will participate in the Virtual Investor Lunch Break Series on June 5, 2024, at 12:00 PM ET. During the event, Mr. Equels will give a corporate overview and discuss the company's business outlook. Attendees can submit questions live, which Mr. Equels will address. The live webcast will be available on the company’s website, and a replay will be accessible for 90 days two hours after the presentation.
AIM ImmunoTech announced a $2 million registered direct offering with a single institutional investor. The deal includes the purchase of 5,640,958 shares of common stock at $0.363 per share and unregistered Class A and Class B warrants to buy an additional 5,640,958 shares each. The Class A warrants expire 18 months from issuance, while Class B warrants expire in five years. Maxim Group acts as the sole placement agent. The gross proceeds are around $2 million before fees and expenses. The offering is made under a shelf registration statement effective since February 4, 2022.
AIM ImmunoTech announced that its CEO, Thomas K. Equels, will participate in two upcoming investor conferences. The first event, the Healthcare Company Showcase hosted by Alliance Global Partners, will take place on May 21, 2024, at 3:20 PM ET. The second event, LIVE! with Webull Corporate Connect: Virtual Biotech Investment Webinar, is scheduled for May 22, 2024, at 3:40 PM ET. Both presentations will be webcast live and accessible via the Events page on AIM ImmunoTech's Investor section of their website.
FAQ
What is the current stock price of Aim Immunotech (AIM)?
What is the market cap of Aim Immunotech (AIM)?
What is AIM ImmunoTech's main focus?
What are AIM ImmunoTech's key products?
What recent achievements has AIM ImmunoTech made?
Who are AIM ImmunoTech's notable partners?
What clinical trials is AIM ImmunoTech currently conducting?
How can investors access AIM ImmunoTech's financial reports?
How does AIM ImmunoTech engage with its stakeholders?
What is the significance of Ampligen in AIM ImmunoTech's portfolio?
Who leads AIM ImmunoTech?
Where can more information about AIM ImmunoTech be found?
